TG Therapeutics Inc. (TGTX) had a rough trading day for Friday December 06 as shares tumbled 7.29%, or a loss of $-0.56 per share, to close at $7.12. After opening the day at $7.78, shares of TG Therapeutics Inc. traded as high as $8.00 and as low as $7.04. Volume was 4.93 million shares over 14,807 trades, against an average daily volume of n/a shares and a total float of 99.56 million.
As a result of the decline, TG Therapeutics Inc. now has a market cap of $708.88 million. In the last year, shares of TG Therapeutics Inc. have traded between a range of $9.38 and $3.32, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.
TG Therapeutics Inc. is based out of New York, NY and has some 120 employees. Its CEO is Michael S. Weiss.